BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Thuris Corporation Names Kevin Lee To Drug Development And Clinical Board


10/19/2005 5:12:36 PM

IRVINE, Calif., Jan. 31 /PRNewswire/ -- Thuris Corporation, a privately held biopharmaceutical company focused on drug development for neurodegenerative diseases and neurological disorders, announced today that Dr. Kevin S. Lee has been appointed to the company's drug development and clinical board. Dr. Lee is the Harrison Foundation Professor and Chair of the Department of Neuroscience, and Professor of Neurological Surgery at the University of Virginia.

Gary Lynch, Ph.D., co-founder and Chief Scientist of Thuris said, "Kevin and I have worked together for many years, and he is as good as they come. I'm quite pleased to welcome him to the Thuris team, and I know that his input will be invaluable."

Kevin S. Lee, Ph.D., said, "It is a pleasure to be involved with the exciting drug development programs at Thuris. Diseases such as stroke exact a major toll on affected individuals, and society as a whole. The programs at Thuris hold great promise for the treatment of debilitating neurological disorders."

Keith B. Hoffman, Ph.D., Chief Operating Officer of Thuris, said, "Thuris is now poised to capitalize on significant scientific advances we've had in-house. Our next phase is to forward our pre-clinical leads into human clinical trials. The addition of Kevin Lee to our advisory board is a validation of our efforts to develop a drug for stroke-related neurological disorders. He is a recognized expert in the field and his involvement should accelerate our ability to get a drug candidate through human clinical trials."

About Thuris

Thuris is focused on pharmaceuticals to treat select Orphan and niche indications in-house, ranging from ischemia-related conditions, brain inflammation, and Huntington's disease. The future pursuit of Alzheimer's disease and Mild Cognitive Impairment will be in alliance with pharmaceutical partners.

Thuris is also the majority shareholder of Izalex, Inc. (R. Scott Greer, CEO), a company based upon the Thuris-invented NeuroGraph, a 510k-cleared, non-invasive medical device that will deliver much-needed objective patient data to the fields of psychiatry and neurology. [http://www.izalex.com]/

About Kevin Lee

Dr. Lee is the Harrison Foundation Professor and Chair of the Department of Neuroscience, and Professor of Neurological Surgery at the University of Virginia. Dr. Lee's laboratory is focused on ischemic pathology, neurovascular communication, and epilepsy. The lab utilizes multiple animal models of ischemic neuronal injury, single and multi-cell recordings, various anatomical/histological techniques, microsurgery, Gamma knife radiosurgery, and other related techniques. Kevin received his Ph.D. from the University of California in 1974, and worked for six years at the Max Planck Institute in Munich, Germany. He has served as a consultant to various pharmaceutical and biotechnology companies over the last 2 decades in the area of neurological disorders.

Thuris Corporation

CONTACT: Thuris Corporation, +1-949-417-4620



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES